BRIDGEWATER, N.J., June 11 /PRNewswire-FirstCall/ -- Alpharma Inc. , a leading global specialty pharmaceutical company, announced today that Thomas J. Spellman III has been appointed as its Executive Vice President, Chief Legal Officer and Corporate Secretary reporting to Dean Mitchell, President and Chief Executive Officer. Mr. Spellman’s career began in a prestigious Wall Street legal firm and includes over a decade of pharmaceutical legal experience. He most recently served as Assistant General Counsel to Johnson & Johnson and prior to that held several key legal assignments at Warner Lambert. Mr. Spellman is replacing the company’s incumbent Chief Legal Officer, Robert Wrobel, who will be retiring following ten years of service.
“I am delighted to appoint Tom as Alpharma’s General Counsel,” commented Dean Mitchell, President and Chief Executive Officer. “Tom’s extensive pharmaceutical expertise and excellent business and legal acumen will be invaluable as the company navigates the next several years of growth and innovation. I want to thank Bob Wrobel for his many years of achievement and dedicated service to the company, and wish him the best in future endeavors.”
Mr. Spellman, a graduate of Cornell Law School, earned his BA from Holy Cross College, is a member of the New York State Bar and began his career as an associate at Simpson Thacher & Bartlett.
Alpharma press releases are also available at our website: http://www.alpharma.com.
Alpharma Inc. is a global specialty pharmaceutical company with leadership positions in products for humans and animals. Alpharma is presently active in more than 60 countries. Alpharma has a growing branded franchise in the chronic pain market with its morphine-based extended release KADIAN(R) product. In addition, Alpharma is among the world’s leading producers of several specialty pharmaceutical-grade bulk antibiotics and is internationally recognized as a leading provider of pharmaceutical products for poultry and livestock.
Contact: Kathleen Makrakis - VP, Investor Relations kathleen.makrakis@alpharma.com 908-566-3916
Alpharma Inc.
CONTACT: Kathleen Makrakis, VP, Investor Relations for Alpharma Inc.,kathleen.makrakis@alpharma.com, +1-908-566-3916
Web site: http://www.alpharma.com/
